PE20200927A1 - Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas - Google Patents
Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanasInfo
- Publication number
- PE20200927A1 PE20200927A1 PE2020000858A PE2020000858A PE20200927A1 PE 20200927 A1 PE20200927 A1 PE 20200927A1 PE 2020000858 A PE2020000858 A PE 2020000858A PE 2020000858 A PE2020000858 A PE 2020000858A PE 20200927 A1 PE20200927 A1 PE 20200927A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- human
- cell receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
UN ANTICUERPO MONOCLONAL O FRAGMENTO DEL MISMO QUE SE UNE A LA REGION DE LA CADENA BETA DE LA FAMILIA TRBV9 DEL RECEPTOR DE LAS CELULAS T HUMANAS, QUE COMPRENDE: 1) UN DOMINIO VARIABLE DE LA CADENA PESADA QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 O SEQ ID NO: 19, CUYAS REGIONES DE COMPLEMENTARIEDAD COMPRENDEN i) LA HCDR 1 COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 1, ii) LA HCDR 2 COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 2, Y iii) LA HCDR 3 COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, O SEQ ID NO: 6; Y 2) UN DOMINIO VARIABLE DE LA CADENA LIGERA QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 11, CUYAS REGIONES DE COMPLEMENTARIEDAD COMPRENDEN i) LA LCDR 1 COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 7, ii) LA LCDR 2 COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 8, Y iii) LA LCDR 3 COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 9. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO QUE ES UTIL EN EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE, ENFERMEDAD CELIACA, LEUCEMIA DE LAS CELULAS T, LINFOMA DE LAS CELULAS T.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017145662A RU2694412C9 (ru) | 2017-12-25 | 2017-12-25 | Моноклональные антитела и способы их применения |
| PCT/RU2018/050168 WO2019132738A1 (ru) | 2017-12-25 | 2018-12-25 | Моноклональные антитела и способы их применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200927A1 true PE20200927A1 (es) | 2020-09-14 |
Family
ID=67002533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000858A PE20200927A1 (es) | 2017-12-25 | 2018-12-25 | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11597767B2 (es) |
| EP (1) | EP3733705A4 (es) |
| JP (1) | JP7339948B2 (es) |
| KR (1) | KR102867660B1 (es) |
| CN (1) | CN111801354B (es) |
| AU (1) | AU2018398341B2 (es) |
| BR (1) | BR112020012959A2 (es) |
| CA (1) | CA3086849A1 (es) |
| CL (1) | CL2020001726A1 (es) |
| CR (1) | CR20200324A (es) |
| EA (1) | EA202091569A1 (es) |
| EC (1) | ECSP20039728A (es) |
| JO (1) | JOP20200161A1 (es) |
| MA (1) | MA50128B1 (es) |
| MX (1) | MX2020006736A (es) |
| NI (1) | NI202000051A (es) |
| PE (1) | PE20200927A1 (es) |
| PH (1) | PH12020551012A1 (es) |
| RU (1) | RU2694412C9 (es) |
| WO (1) | WO2019132738A1 (es) |
| ZA (1) | ZA202003858B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2694412C9 (ru) * | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| RU2712251C1 (ru) | 2018-12-25 | 2020-01-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| AR117735A1 (es) | 2018-12-25 | 2021-08-25 | Joint Stock Company Biocad | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| AU2020224680B2 (en) * | 2019-02-21 | 2025-06-19 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| PE20251393A1 (es) * | 2022-08-18 | 2025-05-22 | Biocad Joint Stock Co | Metodo de tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de celulas t |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| EP2446052B1 (en) | 2009-06-25 | 2018-08-08 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
| EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
| JP6952225B2 (ja) * | 2016-03-18 | 2021-10-20 | 北海道公立大学法人 札幌医科大学 | Ｔ細胞レセプターとその利用 |
| CA3022129A1 (en) | 2016-06-17 | 2017-12-21 | Medigene Immunotherapies Gmbh | T cell receptors and uses thereof |
| RU2694412C9 (ru) * | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
| RU2712251C1 (ru) | 2018-12-25 | 2020-01-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| AR117735A1 (es) | 2018-12-25 | 2021-08-25 | Joint Stock Company Biocad | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO |
-
2017
- 2017-12-25 RU RU2017145662A patent/RU2694412C9/ru active
-
2018
- 2018-12-25 EP EP18895626.2A patent/EP3733705A4/en active Pending
- 2018-12-25 JO JOP/2020/0161A patent/JOP20200161A1/ar unknown
- 2018-12-25 PE PE2020000858A patent/PE20200927A1/es unknown
- 2018-12-25 CN CN201880090210.0A patent/CN111801354B/zh active Active
- 2018-12-25 US US16/957,328 patent/US11597767B2/en active Active
- 2018-12-25 CA CA3086849A patent/CA3086849A1/en active Pending
- 2018-12-25 CR CR20200324A patent/CR20200324A/es unknown
- 2018-12-25 KR KR1020207021655A patent/KR102867660B1/ko active Active
- 2018-12-25 EA EA202091569A patent/EA202091569A1/ru unknown
- 2018-12-25 MX MX2020006736A patent/MX2020006736A/es unknown
- 2018-12-25 BR BR112020012959-3A patent/BR112020012959A2/pt unknown
- 2018-12-25 WO PCT/RU2018/050168 patent/WO2019132738A1/ru not_active Ceased
- 2018-12-25 AU AU2018398341A patent/AU2018398341B2/en active Active
- 2018-12-25 MA MA50128A patent/MA50128B1/fr unknown
- 2018-12-25 JP JP2020535637A patent/JP7339948B2/ja active Active
-
2020
- 2020-06-24 CL CL2020001726A patent/CL2020001726A1/es unknown
- 2020-06-25 PH PH12020551012A patent/PH12020551012A1/en unknown
- 2020-06-25 ZA ZA2020/03858A patent/ZA202003858B/en unknown
- 2020-06-25 NI NI202000051A patent/NI202000051A/es unknown
- 2020-07-13 EC ECSENADI202039728A patent/ECSP20039728A/es unknown
-
2023
- 2023-01-30 US US18/103,194 patent/US12514923B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200927A1 (es) | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20220217A1 (es) | Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| PE20190208A1 (es) | Anticuerpos que reconocen tau | |
| AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
| MX2023011121A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| MX2021000889A (es) | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| PE20211296A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos |